Targeted Protein Degradation – A novel therapeutic modality - Fireside Chat 8 Trailer

In this 45-min interactive virtual exchange on Targeted Protein Degradation: A novel therapeutic modality, we have Chris Nasveschuk, Ph.D., VP - Chemistry at C4 Therapeutics (C4T) in the hot seat, along with Kenneth Barr, Ph.D., Senior Vice President - Discovery Services, Syngene, and Host, Ashu Tandon, CCO, Syngene. Listen to the experts as they share their views on targeted protein degradation and how it can change the course of drug discovery in the days to come.

Key discussion points are as follows:

- How a drug can access previously inaccessible proteins and bring together genetic knock-down and knockout effects
- How to control the extent of protein degradation and how difficult is it to attenuate the degree of modulation of the target protein
- Why the approach of new modalities like Antibody conjugates are viable as compared to traditional medicine
- How C4T’s TORPEDO™ platform, Target ORiented ProtEin Degrader Optimizer, works to accelerate drug design
- C4Ts goals for the next 5 years and how partnership with Syngene fits in with its core strategy

◆ For more information on Drug Discovery Services, write to us at